Cas:1119670-74-4 Propyl4-((2-((4,6-dimethoxy[2,4-14C]pyrimidin-2-yl)oxy)benzyl)amino)benzoate manufacturer & supplier

Chemical Name:Propyl4-((2-((4,6-dimethoxy[2,4-14C]pyrimidin-2-yl)oxy)benzyl)amino)benzoate

CAS.NO:1119670-74-4

Synonyms:Propyl4-((2-((4,6-dimethoxy[2,4-14C]pyrimidin-2-yl)oxy)benzyl)amino)benzoate

Molecular Formula:N/A

Molecular Weight:N/A

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Propyl4-((2-((4,6-dimethoxy[2,4-14C]pyrimidin-2-yl)oxy)benzyl)amino)benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Propyl4-((2-((4,6-dimethoxy[2,4-14C]pyrimidin-2-yl)oxy)benzyl)amino)benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Propyl4-((2-((4,6-dimethoxy[2,4-14C]pyrimidin-2-yl)oxy)benzyl)amino)benzoate Use and application,Propyl4-((2-((4,6-dimethoxy[2,4-14C]pyrimidin-2-yl)oxy)benzyl)amino)benzoate technical grade,usp/ep/jp grade.

Related News: Zynteglo was granted conditional marketing authorisation in May 2019. The conditional authorisation means that there is more evidence to come about the medicine, which the company will provide. EMA regularly reviews new information that becomes available. 3-amino-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-(3-oxo-3,4-dihydroquinoxalin-2-yl)-1H-indole-5-carboxamide manufacturers Wavelength Pharmaceuticals will pay an undisclosed sum to buy up a majority stake in Hyderabad’s Vanamali Organics, an Indian firm specializing in making drug intermediates and starting materials that will add to Wavelengths’ API contract manufacturing work, the company said in a release. 2,5-Bis-(rhodanacetoxy)-2,5-dimethyl-hexin-(3) suppliers The Company most recently announced plans to establish a dedicated laboratory space with Biosafety Level-3 (BSL-3) containment to handle testing of SARS-CoV-2 (the viral strain causing COVID-19) and other similar pathogens that cause human disease. 1,3-Dithiolan-4-one, 2-(2,4,6-trimethylphenyl)- vendor & factory EMA said the drug can help improve the respiratory function of Pompe disease patients, and the most common side effects include hypersensitivity (including anaphylaxis) and infusion-associated reactions.,Zynteglo was granted conditional marketing authorisation in May 2019. The conditional authorisation means that there is more evidence to come about the medicine, which the company will provide. EMA regularly reviews new information that becomes available.